| P2093 | author name string | R H Palmer | |
| | R J Gralla | |
| | S M Grunberg | |
| | E A Perez | |
| | R M Navari | |
| | D Fitts | |
| | H G Kaplan | |
| P2860 | cites work | Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting | Q68447798 |
| | A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group | Q68478567 |
| | The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis | Q68478571 |
| | A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group | Q68478575 |
| | Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group | Q68478579 |
| | Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting | Q70177918 |
| | Antiemetic Efficacy of Tropisetron in Patients Failing Previous Antiemetic Therapy | Q71966087 |
| | Statistical aspects of the analysis of data from retrospective studies of disease | Q27860916 |
| | Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group | Q35978524 |
| | Cancer therapy, vomiting, and antiemetics. | Q37905205 |
| | The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes. | Q38262037 |
| | The clinical role of granisetron (Kytril) in the prevention of chemotherapy-induced emesis. | Q40678486 |
| | Fractionated chemotherapy--granisetron or conventional antiemetics? The Granisetron Study Group | Q40741060 |
| | Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide | Q40754288 |
| | Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. The Nordic Antiemetic Trial Group. | Q40996361 |
| | An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy | Q41206449 |
| | Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin | Q42282060 |
| | A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group | Q44495445 |
| | A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting | Q46514506 |
| | Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. | Q53708801 |
| | A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy | Q67898658 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | granisetron | Q596708 |
| P304 | page(s) | 31-37 | |
| P577 | publication date | 1997-01-01 | |
| P1433 | published in | Supportive Care in Cancer | Q15766919 |
| P1476 | title | Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis | |
| P478 | volume | 5 | |